Chinese contract research organization (CRO) providing drug-discovery and preclinical testing services.
Chinese contract research organization (CRO) providing drug-discovery and preclinical testing services.
Paid per project or per study, mainly by drug developers, so demand follows biotech funding and R&D budgets. Early chemistry and biology work tends to lead customers to keep using it for later safety studies, which keeps clients through a drug's development. Customers are in both China and overseas.
In one line: A China-based WuXi AppTec-style CRO (smaller).
Moat: narrow (scale, customer qualification). Established CRO with qualified GLP labs; switching CROs mid-program is costly.
Headquarters: Shanghai, China · Employees: 2,504
Size Shanghai Medicilon (688202.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.39B, the 1618th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥71.16 on 18 Nov 2026.
Performance Over six months the shares gained 7.9%, against -17.4% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 42.3% over the last twelve months (peer median +6.2%); the operating margin is -1.6% (peer median 7.6%).
Valuation It trades at 85.1× forward earnings against a peer median of 16.9× (3rd most expensive of 17).
Capital Return on invested capital runs 10.6 points below its cost of capital (13.8% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.54B | CN¥1.16B | CN¥1.04B | CN¥1.37B | CN¥1.66B |
| Revenue growth | — | +12% | -24% | -18% | — |
| Gross profit | CN¥486M | CN¥175M | CN¥40.3M | CN¥302M | CN¥658M |
| EBITDA | n/a | -CN¥44.4M | -CN¥219M | CN¥65.4M | CN¥441M |
| Net income | -CN¥46.1M | -CN¥168M | -CN¥331M | -CN¥33.2M | CN¥338M |
| Free cash flow | CN¥53.0M | CN¥47.2M | -CN¥124M | -CN¥150M | -CN¥423M |
| Capital expenditure | CN¥173M | CN¥69.0M | CN¥110M | CN¥186M | CN¥404M |
| Total debt | CN¥330M | CN¥253M | CN¥353M | CN¥389M | CN¥274M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688202.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.1% | -0.5% | 3rd lowest of 21 |
| 6-month return | +7.9% | -17.4% | 6th highest of 21 |
| Distance from 52-week high | -40.7% | -35.4% | 9th lowest of 21 |
| Revenue growth (TTM) | +42.3% | +6.2% | highest of 21 |
| Operating margin | -1.6% | 7.6% | lowest of 21 |
| Forward P/E | 85.1× | 16.9× | 3rd most expensive of 17 |
| ROIC minus cost of capital | -10.6 pp | +0.7 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |
| ICF International ICFI | United States | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% | +4.4% |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| AFRY AFRY.ST | Sweden | $1.42B | +5% | -4% | 7% | 12.5× | -2.2% | +6.3% |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| Yangzhou Tinfulong 603406.SS | China | $1.42B | -29% | -4% | 12% | n/a | 6.1% | +10.6% |
| Shanghai Foreign Service 600662.SS | China | $1.42B | -14% | +1% | 2% | 13.2× | n/a | n/a |
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| Moltiply MOL.MI | Italy | $1.45B | +12% | +20% | 16% | 14.0× | 10.9% | +21.0% |
| Visual China 000681.SZ | China | $1.46B | -34% | -9% | 4% | 37.6× | 57.8% | +6.5% |
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| Guangdong Feinan Resources Recycling 301500.SZ | China | $1.49B | -38% | +42% | 7% | n/a | n/a | n/a |